BlossomHill Therapeutics, Inc.

Clinical-stage cancer drug developer using structure-based design to address resistance. Its lead macrocyclic EGFR inhibitor BH-30643 is in a Phase 1/2 trial for EGFR-mutant lung cancer, alongside a clinical CLK inhibitor for AML and MDS and a preclinical pan-KRAS inhibitor.